It is a 3-(tetramethylcyclopropylmethanoyl)indole derivative related to compounds such as UR-144, A-796,260 and A-834,735, but it is not specifically listed in the patent or scientific literature alongside these other similar compounds, and appears to have not previously been made by Abbott Laboratories, despite falling within the claims of patent WO 2006/069196. XLR-11 was found to produce rapid, short-lived hypothermic effects in rats at doses of 3 mg/kg and 10 mg/kg, suggesting that it is of comparable potency to APICA and STS-135.
Chemical and physical data
Molar mass: 329.459 g·mol?1
A forensic standard for this compound is available, and a representative mass spectrum has been posted on Forendex
XLR-11 has been linked to hospitalizations due to its use
XLR-11 has been linked to acute kidney injury in some users, along with AM-2201.
XLR-11 was banned in New Zealand by being added to the temporary class drug schedule, effective from 13 July 2012.
The U.S. Drug Enforcement Administration (DEA) made the synthetic cannabinoids UR-144, XLR11, and AKB48 Schedule I, illegal drugs under the Controlled Substances Act (CSA) for the next two years as of 16 May 2013.
It has also been banned in Florida as of December 11, 2012.
Arizona banned XLR-11 on 3 April 2013.
XLR-11 is banned in the Czech Republic